an unfavorable prognosis, and patients with PH exhibit a mortality risk seven times higher compared to those without PH. 3 Pulmonary endarterectomy (PEA) is a preferred therapeutic intervention for patients with accessible pulmonary artery lesions in chronic thromboembolic pulmonary hypertension (CTEPH), the predominant etiology within Group IV PH. 5 However, the investigations regarding the efficacy of PEA in the treatment of Group IV PH associated with TAK are notably scarce. In this context, we aim to describe a case of TAK characterized by pulmonary artery involvement and Group IV PH and its management through pulmonary endarterectomy.A 28-year-old female patient was diagnosed with Type V Takayasu arteritis concomitant with Group IV pulmonary hypertension in 2017 [Mean pulmonary artery pressure (PAP): 30 mmHg, Table 1].For induction therapy, the patient received high-dose methylprednisolone (1000 mg/day for 3 days) and cyclophosphamide (500 mg/ week for 3 weeks, 500 mg/10-day for three cycles, and 500 mg/ month for 3 months). Additionally, she was put on tadalafil and vitamin K antagonist therapy. The prednisolone was gradually tapered from an initial 40 mg/day to a maintenance dose of 5 mg/day. Following approximately 6 months of cyclophosphamide therapy, the patient received subcutaneous tocilizumab 162 mg/week. In the course of her echocardiographic assessments, systolic PAP measurements were consistently lower than 40 mmHg. Therefore, we decided to follow up her with serial right heart catheterization (RHC) (Table 1). During follow-up, in 2018, ambrisentan was incorporated into her treatment regimen. In 2019, upon admission for exertional dyspnea, computed tomography angiography (CTA) revealed findings consistent with a TAK flare. Consequently, tocilizumab was discontinued, and infliximab, in conjunction with methotrexate, was initiated. During stable follow-up under treatment, the patient was admitted to our clinic in November 2022 with a 3-month history of worsening dyspnea. At her admission, the patient presented with World Health Organization Functional Capacity (WHO FC) IV, and